CRMDCorMedix Inc.
Price
-30%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, undemanding price, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
CorMedix Inc. (CRMD) reported revenue of $102M in Q2 2026 (quarter ended Jun 30, 2026), up 157% from the same quarter a year earlier. That came with a gross margin of 76% and net income of $26M (25% of revenue). For the full year FY2025, revenue was $312M (+617% year on year) and net income $163M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 19, 2026NJ – October 19, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration.Regulation FD disclosure · press release
- Aug 7, 2026On July 24, 2026, the U.S. District Court for the District of New Jersey (the “District Court”) issued an order granting preliminary approval of the proposed settlement of the consolidated derivative lawsuit captioned In re CorMedix Inc. Derivative Litigation, Case No. 2:21-cv-18493-JXN-LDW (D.N.J) and a related …Other event · Form 8-K
- Jul 2, 2026On June 29, 2026, CorMedix Inc. (the “Company”) effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.